Compare AbCellera Biologics Inc (ABCL) vs Costco Wholesale Corporation (COST) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Costco (COST) trades at $961.80, up 1.22% with strong institutional buying interest. The stock shows bearish technical signals but maintains solid fundamentals with revenue growth to $275.24B in 2025 and consistent earnings beats. Recent March sales surged 11.3% year-over-year, demonstrating resilient consumer demand despite elevated valuation metrics including a P/E of 47.66. Analyst consensus remains strongly bullish with 65.5% buy ratings and a $1,110 price target.

The investment case hinges on Costco's membership-driven model and expansion potential, though high valuation presents near-term risk. Upside depends on sustained comp sales growth and margin expansion, while downside risks include consumer spending pressure and competitive threats. The stock trades 9.9% below its 52-week high, offering potential entry point for long-term investors comfortable with premium valuation.